Viral exposure signature predicts hepatocellular carcinoma

Viral exposure signature predicts hepatocellular carcinoma

(HealthDay)—A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients, according to a study published online June 10 in Cell.

Jinping Liu, Ph.D., of the National Cancer Institute in Bethesda, Maryland, and colleagues used a synthetic human virome technology, VirScan, to perform serological profiling of viral infection history in 899 individuals from a case-control study. A viral exposure signature was developed, and the results were validated in a longitudinal cohort with 173 at-risk patients with long-term follow-up for HCC development.

The researchers found that among at-risk individuals in the validation cohort, the viral exposure signature was significantly associated with HCC status (area under the curve, 0.91 at baseline and 0.98 at diagnosis). The signature was superior to alpha-fetoprotein and identified before .

"Together with existing , the could play an important role in screening people who are at risk for developing HCC. It could help doctors find and treat HCC early," a coauthor said in a statement. "The method is relatively simple and inexpensive, and it only requires a small blood sample."

Several authors are listed as inventors on a U.S. patent application for the viral exposure signature for detection of early-stage HCC.

Explore further

Scientists develop blood test to help improve liver cancer screening

More information: Abstract/Full Text
Journal information: Cell

Copyright © 2020 HealthDay. All rights reserved.

Citation: Viral exposure signature predicts hepatocellular carcinoma (2020, July 13) retrieved 17 May 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors